The Endocannabinoid System: A Complete Guide for Medical Cannabis Patients

What Is the Endocannabinoid System?

• The endocannabinoid system (ECS) is a complex cell-signalling system present in all vertebrates
• It was discovered in the early 1990s during research into how THC interacts with the body
• The ECS comprises three core components: endocannabinoids, receptors, and metabolic enzymes
• It is involved in regulating pain, mood, sleep, appetite, immune function, and memory
• The ECS operates on a “retrograde signalling” principle — sending signals backwards across synapses

The endocannabinoid system is arguably the most important regulatory system you have never been taught about in school. It plays a fundamental role in maintaining homeostasis — the body’s ability to maintain internal balance despite external changes. Understanding the ECS is the first step to understanding why cannabis can affect so many different conditions and symptoms.

Endocannabinoids: The Body’s Own Cannabis

• Anandamide (AEA) — named after the Sanskrit word for bliss — is the primary endocannabinoid
• 2-arachidonoylglycerol (2-AG) is the most abundant endocannabinoid and activates both CB1 and CB2
• Endocannabinoids are synthesised on demand from cell membrane lipids — not stored in advance
• They act locally and are rapidly broken down by enzymes (FAAH degrades AEA; MAGL degrades 2-AG)
• Stress, pain, and exercise all stimulate endocannabinoid production — the basis of “runner’s high”

Unlike most neurotransmitters, endocannabinoids are not stored in vesicles. They are manufactured in real time, in response to physiological demand, and act directly at the synapse where they are needed. This on-demand production makes the ECS uniquely suited to fine-tuning neural activity — and explains why cannabis, which mimics endocannabinoids, can produce such targeted effects.

The Clinical Endocannabinoid Deficiency Hypothesis

• Dr Ethan Russo proposed that some chronic conditions may stem from ECS underactivity
• Migraine, fibromyalgia, and IBS — all treatment-resistant conditions — share low endocannabinoid tone
• This hypothesis explains why cannabis provides disproportionate relief in these conditions
• Factors depleting endocannabinoid tone include chronic stress, sleep deprivation, and poor diet
• Supporting the ECS through cannabis, exercise, and lifestyle changes is an emerging therapeutic strategy

Clinical endocannabinoid deficiency (CED) is a provocative but increasingly influential concept in integrative medicine. If the ECS is chronically underactive, supplementing it with phytocannabinoids from cannabis makes intuitive physiological sense — much like supplementing thyroid hormone in hypothyroidism. While CED remains a hypothesis, it provides a unifying framework for why cannabis helps such a diverse range of conditions.

How Medical Cannabis Modulates the ECS

• THC is a partial agonist at CB1 and CB2 — directly activating these receptors
• CBD is not a direct CB1/CB2 agonist — it works by inhibiting FAAH (raising anandamide levels)
• CBD also modulates serotonin (5-HT1A), adenosine, and TRPV1 receptors
• CBG, CBN, and THCV interact with the ECS and related receptor systems in distinct ways
• Full-spectrum preparations engage the ECS more broadly than isolates — the basis of the entourage effect

Medical cannabis works with your existing endocannabinoid system, not against it. THC supplements or replaces your own endocannabinoids; CBD prolongs the action of those you already produce. This complementary relationship means medical cannabis preparations can be titrated to achieve physiological effects — using the minimum effective dose to nudge the ECS back towards optimal function.